Epizyme Inc (EPZM)

NASDAQ
0.536
-0.026(-4.69%)
Pre Market
0.540
+0.004(+0.65%)
- Real-time Data
  • Volume:
    1,679,495
  • Day's Range:
    0.520 - 0.600
  • 52 wk Range:
    0.440 - 9.860

EPZM Overview

Prev. Close
0.563
Day's Range
0.52-0.6
Revenue
38.49M
Open
0.567
52 wk Range
0.44-9.86
EPS
-2.14
Volume
1,679,495
Market Cap
88.46M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
2,240,050
P/E Ratio
-
Beta
1.29
1-Year Change
-93.93%
Shares Outstanding
164,874,549
Next Earnings Date
Aug 10, 2022
What is your sentiment on Epizyme Inc?
or
Market is currently closed. Voting is open during market hours.

Epizyme Inc News

  • Epizyme Misses Q1 EPS by 3c
    • ByInvesting.com-

    Epizyme (NASDAQ:EPZM) reported Q1 EPS of ($0.38), $0.03 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $8.7 million versus the consensus estimate of...

  • Barclays Stick to Their Buy Rating for Epizyme
    • ByInvesting.com-

    Barclays (LON:BARC) analyst Peter Lawson maintained a Buy rating on Epizyme (NASDAQ:EPZM) on Tuesday, setting a price target of $17, which is approximately 63.30% above the...

Epizyme Inc Analysis

Epizyme Inc Company Profile

Epizyme Inc Company Profile

Employees
250

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellSellSellSellStrong Sell
Technical IndicatorsStrong SellSellBuyStrong SellStrong Sell
SummaryStrong SellSellNeutralStrong SellStrong Sell
  • OKE, shjt , continue waiting
    0
    • https://www.fiercebiotech.com/biotech/gsk-kills-one-barron-s-early-darlings-axing-two-synthetic-lethal-programs-and-epizyme-pact
      0
      • What do you think? Back to 12usd in a year?
        0
        • Copy from Yahoo Finance......interesting.....Does anyone remember what SAVA did last year? It literally dropped to dollar range and shot up over $60 a share over night! All cancer drugs went for a rise with their uptrend. This is a great spot to be in if you can purchase in this range and hold. I could see this creating a lot of millionaires.
          0
      • waiting news and bullish
        0
        • Medium target $22.50, high estimate $36. I like the odd 👍👍
          0
          • and now is 6, do you want buy more?
            0
        • nice terending
          0